Frailty and risk of serious infections in patients with rheumatoid arthritis treated with biologic or targeted‐synthetic DMARDs

Abstract

BackgroundIt remains unknown whether frailty status portends an increased risk of adverse outcomes in patients with rheumatoid arthritis (RA) initiating biologic (b) or targeted synthetic disease modifying anti‐rheumatic drugs (tsDMARDs).MethodsUsing MarketScan data, we identified new users of tumor necrosis factor inhibitors (TNFi), non‐TNFi bDMARDs, or Janus Kinase inhibitors (JAKi) between 2008‐2019, among those with RA. Patients’ baseline frailty risk score was calculated using a Claims‐Based Frailty Index [≥0.2 defined as frail] 12 months prior to drug initiation. The primary outcome was time to serious infection; secondarily, we examined time‐to‐any infection and all‐cause hospitalizations. We used Cox proportional hazards to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CI) and assessed the significance of interaction terms between frailty status and drug class.ResultsA total of 57,980 patients, mean (±SD) age 48.1 ± 10.1 were included; 48,139 (83%) started TNFi, 8111 (14%) non‐TNFi biologics, and 1730 (3%) JAKi. Among these, 3560 (6%) were categorized as frail. Frailty was associated with a 50% increased risk of serious infections (aHR (95% CI): 1.5, 1.2‐1.9) and 40% higher risk of inpatient admissions 1.4 (95% CI, 1.3‐1.6) compared to non‐frail patients among those who initiated TNFi. Frailty was also associated with a higher risk of any infection relative to non‐frail patients among those on TNFi (1.2, 95% CI 1.1‐1.3) or non‐TNFi (1.2, 95% CI 1.0‐1.4) or JAKi (95% CI 1.4, 1.0‐2.0).ConclusionFrailty is an important predictor for the risk of adverse outcomes among patients with RA treated with b‐ or tsDMARDs.This article is protected by copyright. All rights reserved.